AMRX

Amneal Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that develops, manufactures, and distributes generic and specialty pharmaceutical products. Headquartered in Bridgewater, New Jersey, the company was formed through the 2018 merger of Amneal Pharmaceuticals LLC and Impax Laboratories and employs approximately 6,500 people across multiple manufacturing facilities in North America and India. Amneal operates through three primary segments: Generics, Specialty, and BoSS (Biosimilars and Specialty Sterile Injectable). The Generics division offers over 280 product families across various dosage forms, making Amneal one of the largest generic pharmaceutical manufacturers in the United States. The Specialty segment focuses on central nervous system disorders, including migraine treatments and Parkinson's disease therapies, with key products like Rytary and IPX203. The company maintains seven manufacturing facilities and four research and development centers globally, with vertical integration capabilities spanning complex dosage forms including injectables, ophthalmics, and inhalation products. In recent years, Amneal has pursued strategic initiatives to expand its biosimilars portfolio and enhance its specialty pharmaceutical pipeline while streamlining operations to improve profitability. The company generated approximately $2.3 billion in annual revenue and distributes products to major retail chains, wholesalers, and distributors throughout the United States and internationally.